4-Nitrobenzyl bromide is a versatile reagent used in organic synthesis. It is commonly used as a source of the 4-nitrobenzyl group, which can be introduced into various molecules through nucleophilic substitution reactions. The compound itself is typically synthesized by the bromination of 4-nitrotoluene using N-bromosuccinimide (NBS) in the presence of a radical initiator, such as benzoyl peroxide. 4-Nitrobenzyl bromide is known to be a photosensitive compound and can undergo photolysis to generate a reactive radical species. This photolabile property makes it a useful tool in various applications, including the study of protein dynamics and the development of photoremovable protecting groups. In addition to its synthetic applications, 4-nitrobenzyl bromide has also been investigated for its potential pharmacological properties. Some studies have suggested that it may possess anti-inflammatory and antioxidant activities. However, further research is needed to fully understand its biological effects. The compound is also studied extensively in the development of new photo-activated reagents and drugs, as well as for its potential applications in materials science.'
4-nitrobenzyl bromide: structure given in first source
4-nitrobenzyl bromide : A C-nitro compound that consists of nitrobenzene bearing a bromomethyl substituent at the para-position.
ID Source | ID |
---|---|
PubMed CID | 66011 |
CHEMBL ID | 174047 |
CHEBI ID | 62822 |
SCHEMBL ID | 439 |
SCHEMBL ID | 13981949 |
MeSH ID | M0089491 |
Synonym |
---|
1-(bromomethyl)-4-nitro-benzene |
benzene, 1-(bromomethyl)-4-nitro- |
4-nitrobenzyl bromide |
toluene, .alpha.-bromo-p-nitro- |
nsc-4609 |
.alpha.-bromo-4-nitrotoluene |
.alpha.-bromo-p-nitrotoluene |
.alpha.-bromoparanitrotoluene |
100-11-8 |
p-nitrobenzyl bromide |
nitrobenzyl bromide |
toluene, .alpha.-bromo-4-nitro- |
p-(bromomethyl)nitrobenzene |
nsc4609 |
1-(bromomethyl)-4-nitrobenzene |
inchi=1/c7h6brno2/c8-5-6-1-3-7(4-2-6)9(10)11/h1-4h,5h |
AP-065/41884110 |
4-nitrobenzyl bromide, 99% |
toluene, alpha-bromo-4-nitro- |
alpha-bromo-p-nitrotoluene |
ai3-08875 |
toluene, alpha-bromo-p-nitro- |
nsc 4609 |
4-(bromomethyl)nitrobenzene |
alpha-bromoparanitrotoluene |
ccris 7961 |
alpha-bromo-4-nitrotoluene |
einecs 202-820-6 |
STK397280 |
AC-10995 |
AKOS000269732 |
chebi:62822 , |
CHEMBL174047 |
N0181 |
A19507 |
unii-qchrspchue |
qchrspchue , |
tox21_202713 |
NCGC00260261-01 |
dtxsid7049392 , |
cas-100-11-8 |
dtxcid4029351 |
para-nitrobenzylbromide |
a-bromo-p-nitrotoluene |
4-nitrobenzylbromide |
FT-0619218 |
FT-0619217 |
AM20020060 |
CX1172 |
1-bromomethyl-4-nitro-benzene |
SCHEMBL439 |
4-nitrophenylmethyl bromide |
4-nitro benzylbromide |
p-nitrobenzylbromide |
4-nitrobenyl bromide |
p-bromomethylnitrobenzene |
4-nitro-benzyl bromide |
p-nitro benzyl bromide |
1-bromomethyl4-nitrobenzene |
4-nitrobenzylbrornide |
1-bromomethyl-4-nitrobenzene |
4-nitro benzyl bromide |
SCHEMBL13981949 |
1-(bromomethyl)-4-nitrobenzene # |
STR01237 |
W-108975 |
mfcd00007373 |
F2190-0258 |
4-nitrobenzyl bromide, purum, >=97.0% (hplc) |
BP-23489 |
p-nitro-.alpha.-bromotoluene |
p-nitro-a-bromotoluene |
Q26840744 |
EN300-16726 |
p-nitrobenzylbromid |
Z56757346 |
Role | Description |
---|---|
allergen | A chemical compound, or part thereof, which causes the onset of an allergic reaction by interacting with any of the molecular pathways involved in an allergy. |
sensitiser | A chemical compound that causes a substantial proportion of exposed people or animals to develop an allergic reaction in normal tissue after repeated exposure to the compound. |
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Class | Description |
---|---|
C-nitro compound | A nitro compound having the nitro group (-NO2) attached to a carbon atom. |
benzyl bromides | Compounds containing a (bromomethyl)benzene skeleton. |
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
---|---|---|---|---|---|---|---|
hypoxia-inducible factor 1 alpha subunit | Homo sapiens (human) | Potency | 60.8535 | 3.1890 | 29.8841 | 59.4836 | AID1224846 |
estrogen-related nuclear receptor alpha | Homo sapiens (human) | Potency | 6.7715 | 0.0015 | 30.6073 | 15,848.9004 | AID1224841 |
estrogen nuclear receptor alpha | Homo sapiens (human) | Potency | 7.6610 | 0.0002 | 29.3054 | 16,493.5996 | AID743075 |
nuclear factor erythroid 2-related factor 2 isoform 1 | Homo sapiens (human) | Potency | 17.0092 | 0.0006 | 27.2152 | 1,122.0200 | AID743202 |
ATPase family AAA domain-containing protein 5 | Homo sapiens (human) | Potency | 53.7878 | 0.0119 | 17.9420 | 71.5630 | AID651632 |
Ataxin-2 | Homo sapiens (human) | Potency | 53.7878 | 0.0119 | 12.2221 | 68.7989 | AID651632 |
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] |
Process | via Protein(s) | Taxonomy |
---|---|---|
protein binding | ATPase family AAA domain-containing protein 5 | Homo sapiens (human) |
ATP binding | ATPase family AAA domain-containing protein 5 | Homo sapiens (human) |
ATP hydrolysis activity | ATPase family AAA domain-containing protein 5 | Homo sapiens (human) |
DNA clamp unloader activity | ATPase family AAA domain-containing protein 5 | Homo sapiens (human) |
DNA binding | ATPase family AAA domain-containing protein 5 | Homo sapiens (human) |
RNA binding | Ataxin-2 | Homo sapiens (human) |
epidermal growth factor receptor binding | Ataxin-2 | Homo sapiens (human) |
protein binding | Ataxin-2 | Homo sapiens (human) |
mRNA binding | Ataxin-2 | Homo sapiens (human) |
[Information is prepared from geneontology information from the June-17-2024 release] |
Process | via Protein(s) | Taxonomy |
---|---|---|
Elg1 RFC-like complex | ATPase family AAA domain-containing protein 5 | Homo sapiens (human) |
nucleus | ATPase family AAA domain-containing protein 5 | Homo sapiens (human) |
cytoplasm | Ataxin-2 | Homo sapiens (human) |
Golgi apparatus | Ataxin-2 | Homo sapiens (human) |
trans-Golgi network | Ataxin-2 | Homo sapiens (human) |
cytosol | Ataxin-2 | Homo sapiens (human) |
cytoplasmic stress granule | Ataxin-2 | Homo sapiens (human) |
membrane | Ataxin-2 | Homo sapiens (human) |
perinuclear region of cytoplasm | Ataxin-2 | Homo sapiens (human) |
ribonucleoprotein complex | Ataxin-2 | Homo sapiens (human) |
cytoplasmic stress granule | Ataxin-2 | Homo sapiens (human) |
[Information is prepared from geneontology information from the June-17-2024 release] |
Assay ID | Title | Year | Journal | Article |
---|---|---|---|---|
AID67618 | Drug concentration required to achieve 50% kill of EMT6 cells under oxygenated conditions. | 1980 | Journal of medicinal chemistry, Aug, Volume: 23, Issue:8 | Nitrobenzyl halides and carbamates as prototype bioreductive alkylating agents. |
AID1524436 | Substrate activity at recombinant Haemophilus influenzae Chloramphenicol nitroreductase expressed in Escherichia coli assessed as initial rate of reaction at 150 uM measured at 30 sec interval for 5 mins in presence of NADPH at pH 8 under 37 degC by UV-vi | 2019 | Bioorganic & medicinal chemistry letters, 05-01, Volume: 29, Issue:9 | Investigating the promiscuity of the chloramphenicol nitroreductase from Haemophilus influenzae towards the reduction of 4-nitrobenzene derivatives. |
AID232392 | Ratio of ED50 (aerobic) to ED50 (hypoxic) | 1980 | Journal of medicinal chemistry, Aug, Volume: 23, Issue:8 | Nitrobenzyl halides and carbamates as prototype bioreductive alkylating agents. |
AID67617 | Drug concentration required to achieve 50% kill of EMT6 cells under hypoxic conditions. | 1980 | Journal of medicinal chemistry, Aug, Volume: 23, Issue:8 | Nitrobenzyl halides and carbamates as prototype bioreductive alkylating agents. |
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 1 (16.67) | 18.7374 |
1990's | 1 (16.67) | 18.2507 |
2000's | 1 (16.67) | 29.6817 |
2010's | 3 (50.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.
| This Compound (38.84) All Compounds (24.57) |
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 2 (28.57%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 5 (71.43%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |